Replimune Group, Inc. (NASDAQ:REPL)
| Market Cap | 1.09B+184.6% |
| Revenue (ttm) | 0 |
| Net Income | -297.01M-6.0% |
| EPS | -3.15+6.8% |
| Shares Out | 84.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,789.332 |
| Open | 13.18 |
| Previous Close | 13.20 |
| Day's Range | 12.92 - 13.46 |
| 52-Week Range | 1.50 - 16.33 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 18.67(+43.56%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About REPL
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$REPL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in REPL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by REPL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
REPL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New REPL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to REPL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in REPL
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $34.53M |
| VTIVanguard Morningstar Total Stock Market ETF | $30.18M |
| IWMiShares Russell 2000 ETF | $27.89M |
| VXFVanguard Extended Market ETF | $13.33M |
| IBBiShares Biotechnology ETF | $8.73M |
| VTWOVanguard Russell 2000 ETF | $6.96M |
Estimated from each fund’s disclosed top holdings × AUM
REPL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from REPL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score